AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)’s share price gapped up prior to trading on Friday . The stock had previously closed at $3.84, but opened at $3.95. AVEO Pharmaceuticals shares last traded at $3.81, with a volume of 5,167,657 shares traded.

AVEO has been the subject of a number of recent research reports. Zacks Investment Research raised AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a report on Monday, July 24th. Piper Jaffray Companies upped their target price on AVEO Pharmaceuticals from $3.80 to $4.50 and gave the stock an “overweight” rating in a report on Monday, August 28th. FBR & Co reaffirmed an “outperform” rating and issued a $3.00 target price on shares of AVEO Pharmaceuticals in a report on Thursday, July 13th. BidaskClub raised AVEO Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 16th. Finally, ValuEngine raised AVEO Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, June 24th. One analyst has rated the stock with a sell rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $3.42.

The firm’s 50 day moving average is $3.61 and its 200 day moving average is $1.93. The company’s market capitalization is $454.30 million.

Large investors have recently made changes to their positions in the stock. Fore Research & Management LP purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at about $111,000. Clear Harbor Asset Management LLC purchased a new position in AVEO Pharmaceuticals during the 2nd quarter valued at about $289,000. Cannell Peter B & Co. Inc. increased its holdings in AVEO Pharmaceuticals by 22.9% during the 2nd quarter. Cannell Peter B & Co. Inc. now owns 109,875 shares of the biopharmaceutical company’s stock valued at $244,000 after purchasing an additional 20,500 shares during the period. Paloma Partners Management Co purchased a new position in AVEO Pharmaceuticals during the 1st quarter valued at about $184,000. Finally, UBS Oconnor LLC purchased a new position in AVEO Pharmaceuticals during the 1st quarter valued at about $291,000. Institutional investors own 53.76% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “AVEO Pharmaceuticals, Inc. (AVEO) Shares Gap Up to $3.95” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/aveo-pharmaceuticals-inc-aveo-shares-gap-up-to-3-95/1617037.html.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.

Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.